Kamala Harris is focusing on expanding the Biden administration's efforts to address the issue of high prescription drug costs in the United States. One of the key aspects of her health care platform is the proposal to extend the current $35 monthly cap on out-of-pocket costs for insulin and the upcoming $2,000 annual limit on out-of-pocket costs for prescription drugs to all Americans, not just those enrolled in Medicare.
These cost caps were initially introduced for Medicare beneficiaries through the Inflation Reduction Act. The $2,000 limit on out-of-pocket costs for Medicare Part D drugs is set to take effect in January, aiming to provide relief to seniors facing high prescription expenses.
